跳到正文
原文
STAT 主站· Adam Feuerstein·· 2026-10-01AI 评分57

Invivyd III期LIBERTY研究:单抗VYD2311接种后不良事件发生率显著低于Comirnaty

STAT+: Invivyd’s pursuit of a Covid vaccine alternative gets a lift, but an FDA hurdle may await

AI 导读

Invivyd公布III期LIBERTY研究结果,评估其注射型单克隆抗体VYD2311在预防新冠疫情中的安全性。6天时,VYD2311组参与者在注射部位或全身报告头痛、寒战、疲劳或疼痛的比例为57%,显著低于对照疫苗Comirnaty组的91%。

正文

This story first appeared in Adam’s Biotech Scorecard, a STAT newsletter. Sign up here to get it delivered to your inbox. And subscribe to STAT+ to get an unabridged version, with exclusive content.

An update on Invivyd, the small biotech company developing an injectable, low-dose monoclonal antibody to protect against Covid-19 infection like a vaccine does, but without the real or perceived limitations of vaccines. I last wrote about Invivyd in this newsletter in August 2025.

On Tuesday, Invivyd reported the results from a Phase 3 study called LIBERTY that demonstrated the superior safety and tolerability of its antibody candidate, VYD2311, compared against Comirnaty, the established mRNA-based Covid vaccine marketed by Pfizer. After six days, 57% of study participants who had VYD2311 injected into the muscle of their upper arm reported headaches, chills, fatigue or pain at the injection site — the typical side effects associated with vaccinations. In the Comirnaty arm of the study, 91% of participants reported the same side effects. The difference was statistically significant. The same study showed VYD2311 was also better tolerated at 56 days, and could be combined safely with Comirnaty.

Continue to STAT+ to read the full story…

来源:STAT 主站 · statnews.com